Clinical trial of DprE1 inhibitors: from bench to bedside
Abstract
The DprE1 enzyme is a viable target for creating new antituberculosis (TB) medications. It is essential for synthesizing the mycobacterial cell wall's important components called arabinans. Inhibition of DprE1 can lead to the cell lysis of Mycobacterium tuberculosis (Mtb). Several DprE1 inhibitors have been developed and tested in preclinical studies. BTZ043, PBTZ169, TBA-7371, and OPC-167832 are some of the inhibitors that have exhibited excellent activity against TB both in vitro and in animal models. The mode of action is unique and different from the first-line drug ethambutol (EMB) (inhibits the arabinosyltransferases). TBA-7371 completed phase 2 trials, and the phase 2a clinical trials for PBTZ169 were terminated due to low enrolment. Meanwhile, BTZ043 and OPC-167832 are currently in phase 2 trials. This review provides an overview of the discovery, synthesis, preclinical, and clinical studies of DprE1 inhibitors, which have entered clinical trials. Article Highlights DprE1 inhibitors are a new class of anti-TB drugs that target the DprE1 enzyme. DprE1 enzyme is essential for the synthesis of the Mtb cell wall. Four DprE1 inhibitors are in clinical trials. DprE1 inhibitors are a new class of anti-TB drugs that target the DprE1 enzyme. DprE1 enzyme is essential for the synthesis of the Mtb cell wall. Four DprE1 inhibitors are in clinical trials.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.